Improved recovery between sessions becomes more apparent
They are not approved for human or veterinary administration, are not evaluated by the FDA or EMA, and must not be used as drugs, supplements, or cosmetic products
At standard doses of 1 mg or less daily, side effect rates were similar to placebo
In a phase 3 trial involving adults with overweight or obesity (BMI 28 kg/m, or 24 kg/m with at least one weight-related comorbidity) without diabetes, treatment with 2.4 mg ecnoglutide produced a mean body weight reduction of 13.2% at 40 weeks
The muscle-sparing effect represents a significant advantage for body recomposition goals
Girnita is a physician-scientist double-board certified in rheumatology and internal medicine, trained at Harvard, with a PhD in immunology